Eli Lilly Acquires SiteOne in $1B Pain Drug DealEli LillyEli Lilly has acquired SiteOne Therapeutics in a deal worth up to $1 billion to develop STC-004, a promising non-opioid NaV1.8 inhibitor for chronic pain, advancing next-gen, addiction-free pain therapies.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
